Product
Choline Salicylate
1 clinical trial
7 indications
Indication
Hodgkin LymphomaIndication
Non-Hodgkin LymphomaIndication
Multiple MyelomaIndication
Histiocytic and Dendritic Cell NeoplasmIndication
Hodgkin's LymphomaIndication
Refractory Non-Hodgkin LymphomaClinical trial
Phase Ib Trial of Low-Dose Selinexor (KPT-330) in Combination With Choline Salicylate (CS) for the Treatment of Patients With Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasms, or Multiple MyelomaStatus: Recruiting, Estimated PCD: 2024-12-15